Thomas Hope
University of California, San Francisco · Alliance for Clinical Trials in Oncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
15
all conditions, ClinicalTrials.gov
NIH grants tied to them
3
36 more share only the name and are not shown
Trial papers
38
PubMed author-name match
Trials
Studies that name Thomas Hope as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 20:52 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07218224 · Expanded Access:18F-Fluorocholine for the Detection of Parathyroid AdenomasThomas Hope · available · Parathyroid Adenomas · principal investigator
- Ph3NCT07200830 · Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL TrialAlliance for Clinical Trials in Oncology · recruiting · Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 · study chair
- Ph2NCT06961084 · Comparison of I-124 PET/CT for the Diagnosis of Thyroid CancerThomas Hope · recruiting · Thyroid Cancer · principal investigator
- N/ANCT05435495 · Mechanisms of Resistance to PSMA Radioligand TherapyUniversity of California, San Francisco · recruiting · Prostate Cancer · principal investigator
- Ph3NCT04895631 · 18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid AdenomasThomas Hope · completed · Hyperparathyroidism, Primary · principal investigator
- Ph1NCT04621435 · Imaging of Solid Tumors Using FAP-2286Thomas Hope · recruiting · Solid Tumors, Adult, Metastatic Cancer · principal investigator
- N/ANCT04377152 · Expanded Access 68Gallium-PSMA-11 PET for Prostate CancerUniversity of California, San Francisco · approved for marketing · Prostate Cancer, Prostate, Prostate Adenocarcinoma · principal investigator
- Ph3NCT03803475 · Gallium-68 PSMA-11 PET Imaging in Prostate Cancer PatientsThomas Hope · completed · Prostate Cancer · principal investigator
- Ph2/Ph3NCT03764007 · 18F-Fluorocholine for the Detection of Parathyroid AdenomasThomas Hope · completed · Hyperparathyroidism, Primary · principal investigator
- Ph3NCT03353740 · Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical RecurrenceThomas Hope · completed · Prostate Cancer · principal investigator
- Early Ph1NCT03197012 · Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine TumorThomas Hope · completed · Neuroendocrine Tumor · principal investigator
- Ph2/Ph3NCT02919111 · Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy PatientsUniversity of California, San Francisco · completed · Prostate Cancer · principal investigator
- Ph2/Ph3NCT02918357 · Gallium-68 PSMA-11 PET in Patients With Biochemical RecurrenceUniversity of California, San Francisco · completed · Prostate Cancer · principal investigator
- Ph2NCT02611882 · Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer PatientsThomas Hope · completed · Prostate Cancer · principal investigator
- N/ANCT02233595 · Evaluation of Rectal Cancer Treatment Response Using PET/MRIUniversity of California, San Francisco · terminated · Rectal Adenocarcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 20:52 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 36 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- MELT: Modulation of PSMA Expression for Lutetium TherapyR01CA235741 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2019 to 2025 · $455,810 awarded in 2025Grant number is on one of their registry trials
- Qualification and Harmonization of PET/MRI for Cancer Clinical TrialsR01CA212148 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2017 to 2022 · $200,396 awarded in 2022Same name and institution; not confirmed by an ID
- Immunogenic Priming with Lu-PSMA Targeted Therapy in Advanced Prostate CancerR01CA229354 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2019 to 2020 · $368,455 awarded in 2020Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 20:52 UTC. The ranking covers the 200 most relevant of 38 PubMed records, and a shared surname and initials can bring in a namesake. All 38 on PubMed
- Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.JAMA Oncol · 2019684 citationsRCR 31.4
- 399 citationsRCR 17.6
- 325 citationsRCR 20.6
- Sleep in the laboratory and sleep at home: comparisons of older insomniacs and normal sleepers.Sleep · 1997152 citationsRCR 5.9
- Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease.Brain Res · 2003133 citationsRCR 3.6
- 68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study.J Nucl Med · 2017126 citationsRCR 4.9
- Impact of 68Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial.J Nucl Med · 2020102 citationsRCR 5.0
- Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer's disease prospectively assessed for behavioural changes.Neuropathol Appl Neurobiol · 2000100 citationsRCR 2.5
- 87 citationsRCR 7.7
- 111In-Pentetreotide Scintigraphy Versus 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden.J Nucl Med · 201984 citationsRCR 4.5